RheumNow Week in Review – 17 June 2016
Dr. Jack Cush reviews the news, reports and highlights from EULAR and the last 2 weeks from RheumNow.com.
News
AMA Promotes Training in Telemedicine
Recognizing that formalized training in telemedicine is not widely offered to physicians-in-training, the American Medical Association (AMA) adopted policy during its Annual Meeting aimed at ensuring medical students and residents learn how to use telemedicine in clinical practice.
European Registries Show No Melanoma Risk with Biologics
The combined analysis of 130,315 rheumatoid arthritis patients from 11 European registries did not reveal an association between invasive (malignant) melanoma and the use of biologic therapies.
Arthritis and Suicide Linked with Childhood Adversities
Men and women with arthritis have nearly a two-fold higher prevalence of lifetime suicide attempts than those without arthritis, according to a recent study from the University of Toronto.
Dramatic Results for Interferon Blocker in SLE
Blocking the type 1 interferon receptor with the monoclonal antibody anifrolumab shows promise as a treatment for moderate-to-severe systemic lupus erythematosus (SLE), according to a phase IIb study presented here.
Long-Acting Opioids Associated with Higher Mortality Risk
Prescription of long-acting opioids for chronic noncancer pain was associated with an increased risk of all-cause mortality, including deaths from causes other than overdose, compared with anticonvulsants or cyclic antidepressants, according to a study appearing in the June 14 issue of JAMA.
No Increased Risk of Colitis Flares in Secukinumab Trials
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
Parathyroidectomy Improves and Bisphosphonates Worsen Fracture Risk in Primary Hyperparathyroidism
A retrospective observational study of over 6000 patients with primary hyperparathyroidism (PHPT), followed in the Kaiser-Permanente system, has shown a greater need for parathyroidectomy than was previously thought.
U-ACT-Early and the Benefits of Tocilizumab
Lancet has published the results of the U-ACT-early study assessing the efficacy of monotherapy versus combination therapy using an interleukin-6 receptor-blocking monoclonal antibody, tocilizumab, in patients with rheumatoid arthritis.
Ixekizumab Success with the UNCOVER Trials in Psoriasis
The NEJM today published the results of two phase-3 trials (UNCOVER-2 and UNCOVER-3) demonstrating the efficacy of ixekizumab (a monoclonal antibody against interleukin-17A) in the treatment of moderate-to-severe psoriasis.
Pre-Clinical Use of Rituximab Forestalls Rheumatoid Onset
The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.
Hospitalizations Decline for Rheumatoid Arthritis, But Increase in Gout
JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.
